A 35-year-old female patient is undergoing hormone replaceme…
A 35-year-old female patient is undergoing hormone replacement therapy (HRT) following a total hysterectomy. She expresses concern over frequent dosing and inconsistent symptom relief. The prescriber is considering switching her to a transdermal oestradiol system. You are tasked with evaluating and advising on the best dosage form design to optimize therapeutic outcomes while minimizing systemic side effects.Which physicochemical property of oestradiol makes transdermal delivery particularly suitable for sustained systemic absorption in hormone replacement therapy?
Read Details2. Mr. M is a 56-year-old male from Ga-Rankuwa with an 8-yea…
2. Mr. M is a 56-year-old male from Ga-Rankuwa with an 8-year history of hypertension, dyslipidaemia, obesity (BMI 33 kg/m²), and stage 3 chronic kidney disease (eGFR 48 mL/min/1.73m²). He is currently managed on metformin 1g bd, glibenclamide 5mg bd, enalapril 10mg bd, and simvastatin 20mg nocte, but presents with poor glycaemic control (HbA1c 9.2%, fasting glucose 11.5 mmol/L), elevated blood pressure (148/92 mmHg), and frequent hypoglycaemic episodes, particularly in the late afternoon. His condition is further complicated by irregular meal patterns due to shift work, poor adherence to lifestyle modifications, and reliance on public sector healthcare with limited financial resources. He has lately felt that he is gaining weight as well. 2.1 Critically evaluate Mr. M’s current healthcare problems, pharmacotherapy and design a comprehensive, patient-specific management plan. In your discussion include:2.1.1 Identification of problems (4)2.1.2 Critical Evaluation of current therapy (3)2.1.3 Formulation of Therapeutic Plan (10)
Read Details